Therapies that activate the patient’s immune system to destroy cancer are known as cancer immunotherapies. One type of immunotherapy consists of monoclonal antibodies. These are proteins that stick to one specific target typically expressed on cancer cells. Once bound to the cancer cell, monoclonal antibodies activate other parts of the immune system to destroy the cancer cell.
Other types of cancer immunotherapies activate cells called T cells. T cells circulate throughout the entire body until they encounter a cancer cell. Once attached, T cells kill tumor cells and move on to recognize and kill other cancer cells.
Cancer immunotherapies are arguably one of the most promising treatments for patients with advanced cancers such as melanoma and lung cancer. The results of various immunotherapy clinical trials have shown great promise, and immunotherapies are achieving responses never seen before in specific types of cancers. Below are examples of cancer immunotherapies and trials ongoing at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Checkpoint Inhibitors – Taking the Brakes Off the Body’s Immune System
Cancer cells put up defenses so they can’t be detected by the body’s immune system. One of the ways they do this is to render the immune system ineffective by presenting proteins that turn off response from T cells–the immune cells that kill tumor cells. Therapies known as “checkpoint inhibitors” work by blocking these proteins so that T cells can be activated to recognize cancer cells as foreign invaders.
One example of a checkpoint inhibitor is anti-CTLA-4. CTLA-4 is normally expressed on the surface of T cells. Tumor cells can activate the CTLA-4 pathway to suppress T cell activity. However, therapies such as ipilimumab block the CTLA-4 and restore tumor immunity.
Program death-1 (PD-1) is another protein found on the surface of T cells. PD-1 is a negative regulator of T cells and thus inhibits their antitumor responses. PD-1 interacts with PD-L1 and PD-L2 which are found on cancer cells as well as other types of cells within the tumor. Therefore, therapies that block PD-1 (such as pembrolizumab and nivolumab) or PD-L1 (atezolizumab) or PD-L2 can prevent the T cells from becoming suppressed and can reinvigorate antitumor immune responses.
Therapies that help maintain T cell function can also be used alone or in combination with checkpoint inhibitors to increase antitumor T cell responses. One such example is indoximod. Indoximod blocks the enzyme indoleamine 2,3-dioxygenase (IDO). Inhibiting IDO helps maintain high levels of an essential amino acid called tryptophan which is critical for T cell function. Another example is interleukin-2 (IL-2) therapy, a protein or cytokine that helps stimulate various types of immune cells including T cells. IL-2 has been approved for cancer treatment.
Related Trials at UMGCCC
|Acute Myeloid Leukemia (AML)||1550GCC||II||Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy||Maria Baer, MD|
|Acute Myeloid Leukemia (AML)||1562GCC||I/II||A Phase 1b / Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)||Ashkan Emadi, MD|
|Bladder||1680GCC||II||A Randomized, Double-Blind, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-Line Chemotherapy in Patients with Metastatic Urothelial Cancer||Heather Mannuel, MD|
|Bladder, Lung, or Ovary||16101GCC||I||A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4||Heather Mannuel, MD|
|Lung (NSCLC)||1607GCC||I/II||A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-Line Treatment Alone or in Combination with Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)||Dan Zandberg, MD|
|Lung (NSCLC)||1629GCC||II||Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients with Chemotherapy Naïve State IV Non-small Cell Lung Cancer||Dan Zandberg, MD|
|Lung (NSCLC)||EA5142||III||Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase II Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers||Katherine Scilla, MD|
|Lung (NSCLC -Squamous Cell)||SWOG1400F||III||A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)||Katherine Scilla, MD|
|Lung (NSCLC)||SWOG1400I||III||A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-study)||Katherine Scilla, MD|
Monoclonal Antibodies (mAbs) – Synthetic Proteins Enhancing the Immune System
The immune system uses antibodies, or proteins, to recognize foreign invaders such as cancer cells. Monoclonal antibodies, or mAbs, are synthetic proteins that can bind to specific receptors (antigens) on cancer cells. Once bound to the antigen, mAbs signal to other parts of the immune system to come and destroy the cancer cell.
Related Trials at UMGCCC
|Acute Lymphoblastic Leukemia (ALL)||E1910||III||A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
||Maria Baer, MD|
|Acute Myeloid Leukemia (AML)||1564GCC||I||Phase I Trial of Brentuximab Vedotin Combined with Re-induction Chemotherapy in Patients with Relapsed of Refractory, CD30-expressing Acute Myeloid Leukemia (AML)
||Ashkan Emadi, MD|
|Acute Myeloid and Monocytic Leukemia (AML)||1718GCCC-S1||I/II||Targeting CD200 with Samalizumab to Enhance Outcomes in Elderly Untreated Core-Binding Factor Acute Myeloid Leukemia||Maria Baer, MD|
|Acute Myeloid and Monocytic Leukemia (AML)||1718GCCC-S2||I/II||Phase Ib/II Study of BI 836858 with Azacitidine in Previously Untreated AML Patients >/=60 Years With Unique Molecular Features||Maria Baer, MD|
|Acute Myeloid and Monocytic Leukemia (AML)||1718GCCC-S3||II||A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy||Maria Baer, MD|
|Acute Myeloid and Monocytic Leukemia (AML)||1718GCCC-S4||I/II||A Phase Ib/II Study of Entosplentinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with Mixed Lineage Leukemia (MLL) Gene Re-arrangements and/or MLL-Partial Tandem Duplications||Maria Baer, MD|
|Bladder; Lung; Ovary||16101GCC||I||A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4||Heather Mannuel, MD|
|Breast||1654GCC||II||Phase II Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)||Kate Tkaczuk, MD|
|Breast; Colon||1600GCC||I||GS-US-294-0101: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors||Paula Rosenblatt, MD|
|Colon||A021502||III||A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair||Cherif Boutros, MD|
|Kidney||1638GCC||II||A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma||Arif Hussain, MD|
|Lymphoma (Hodgkin's, Non-Hodgkin's)||1759GCCC||II||A Phase 2B Randomized Study to Assess the Efficacy and Safety of Combination Ublituximab + TGR-1202 and TGR-1201 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma||Jennie Law, MD|
|Multiple Myeloma||16102GCC||II||Phase II, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Patients With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation||Ashraf Badros, MD|
|Ovary||1533GCC||II||A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
||Gautam Rao, MD|
|Pediatric B-Lymphoblastic Leukemia||AAL1331||III||Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (ALL)
||Teresa York, MD|
|AEWS1221||II||Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma||Teresa York, MD|
Cancer Vaccines – Training the Immune System to Recognize Cancer
Related Trials at UMGCCC
|Head and Neck||1666GCC||II||A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral Cavity||Dan Zandberg, MD|
|Multiple Myeloma||1611GCC||II||Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusion||Aaron Rapoport, MD|
Gene-modified Immune Cells
Thanks to advances in modern genetics, it is now possible to extract a patient's own T cells, genetically modify them in ways that make them more effective in detecting and fighting cancer, and deliver them back to the patient. This approach was first pioneered at UMGCCC for the treatment of blood cancers, and now researchers are using gene-modified T cells to equip patients' immune systems to fight non-small cell lung cancer.
Related Trials at UMGCCC
|Acute Lymphoblastic Leukemia||1567GCC||I/II||Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Philadelphia Chromosome-Negative Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia||Maria Baer, MD|
|Lung and Other Respiratory and Intrathoracic Sites||1556GCC||I/II||A Phase I/II Dose Escalation Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)||Nancy Hardy, MD|
|Multiple Myeloma||1767GCCC||Pilot||Open-Label Randomized Pilot Study To Assess The Safety, Tolerability And Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone Or In Combination With Pembrolizumab In HLA-A2+ Subjects With NY-ESO-1 And/Or LAGE 1A Positive Relapsed and Refractory Multiple Myeloma||Aaron Rapoport, MD|
Sometimes immunotherapies are rendered more efficacious when combined with other modalities. For example, radiation therapy and immunotherapy used together can create a synergistic result greater than the sum of its parts.
Related Trials at UMGCCC
|Brain||1344GCC||Pilot||Pilot Study of Combined Optune, Bevacizumab, and Hypofractionated Stereotactic Irradiation for Bevacizumab-Naïve, Recurrent Glioblastoma||Young Kwok, MD|
|Head and Neck||1456GCC||II||A Phase II Trial of Reirradiation Combined with Open Label MK-3475 in Patients with Locoregional Inoperable Recurrence of Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Dan Zandberg, MD|
|Head and Neck||0920RTOG||III||A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer||James Snider, MD|
|Soft Tissue (Sarcoma)||1711GCCC||I/II||Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma||Vincent Ng, MD|